Monday, September 20, 2021 4:13:07 PM
Zacks Equity Research
Mon, September 20, 2021, 11:40 AM
ZTS
+0.14%
COLL
-1.01%
Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Collegium Pharmaceutical and Zoetis are sporting Zacks Ranks of #1 (Strong Buy) and #3 (Hold), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that COLL has an improving earnings outlook. However, value investors will care about much more than just this.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
COLL currently has a forward P/E ratio of 5.31, while ZTS has a forward P/E of 43.84. We also note that COLL has a PEG ratio of 0.27. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. ZTS currently has a PEG ratio of 3.17.
Another notable valuation metric for COLL is its P/B ratio of 2.76. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, ZTS has a P/B of 21.62.
Based on these metrics and many more, COLL holds a Value grade of A, while ZTS has a Value grade of C.
COLL stands above ZTS thanks to its solid earnings outlook, and based on these valuation figures, we also feel that COLL is the superior value option right now.
https://finance.yahoo.com/news/coll-vs-zts-stock-value-154003011.html
Recent COLL News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/10/2024 12:03:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 12:02:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:07:12 PM
- Collegium Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 08:02:00 PM
- Collegium Announces CEO Transition • GlobeNewswire Inc. • 05/09/2024 08:01:00 PM
- Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Collegium to Report First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:26:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 10:24:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 09:39:36 PM
- Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results • GlobeNewswire Inc. • 02/22/2024 09:09:56 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 09:03:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:01:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:15:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:14:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:14:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:14:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:13:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:04:28 PM
- Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 09:19:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/16/2024 09:20:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 01:03:11 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM